Skip to main content
Fig. 1 | Critical Care

Fig. 1

From: Toward the personalized and integrative management of voriconazole dosing during COVID-19-associated pulmonary aspergillosis

Fig. 1

Biological findings for a COVID-19 patient treated with voriconazole in the context of pulmonary aspergillosis. MR metabolite ratios (voriconazole N-oxide /voriconazole), DXM dexamethasone. The dose regimen of voriconazole is depicted in blue, the voriconazole trough plasma concentration in red, and MR in green. Voriconazole was not administered on the evening of November 10, 2020, nor the morning or evening of November 11, 2020

Back to article page

Critical Care

ISSN: 1364-8535